Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 8/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575871 | 0.83 | ABCB11 (0.54) | GRIA4HSD17B10CYP2C9PTGS2ABCB11 | |
| SCHEMBL6565123 | 0.82 | GRIA4 (0.68) | GRIA4 | |
| SCHEMBL6572001 | 0.82 | GRIA4 (0.55) | GRIA4HSD17B10CYP2C9 | |
| SCHEMBL6759350 | 0.80 | GRIA4 (0.47) | GRIA4HSD17B10PTGS2ABCB11KDM4E | |
| SCHEMBL5992695 | 0.78 | GRIA4 (0.71) | GRIA4 | |
| SCHEMBL6573583 | 0.78 | GRIA4 (0.48) | GRIA4HSD17B10PTGS2ABCB11KDM4E | |
| SCHEMBL6763013 | 0.78 | GRIA4 (0.43) | GRIA4HSD17B10PTGS2ABCB11KDM4E | |
| SCHEMBL6762651 | 0.77 | GRIA4 (0.47) | GRIA4HSD17B10CYP2C9PTGS2ABCB11 | |
| SCHEMBL6762961 | 0.76 | KDM4E (0.44) | GRIA4PTGS2KDM4E | |
| SCHEMBL6763807 | 0.76 | ALDH1A1 (0.47) | GRIA4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1409452-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002098846-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | GRIA4 9/4885HSD17B10 1260/4885CYP2C9 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.